Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
Akesobio Australia Pty Ltd
This study includes a dose escalation and dose expansion phase. In the dose escalation phase (phase 1a) a maximum tolerated dose (MTD) or recommended phase 2 dose will be determined for AK-105 as a single agent. The dose expansion phase will only be open to patients with specific tumour types. All patients will receive AK-105 by intravenous administration.